Company
Headquarters: Chengdu, China
Employees: 408
CN¥9.51 Billion
CNY as of Jan. 1, 2026
US$1.36 Billion
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Chengdu Kanghua Biological Products Co., Ltd. engages in the research, development, production, sale, and technical service of biological products in China. It offers group ACYW135 meningococcal polysaccharide vaccines; and freeze-dried human diploid cell rabies vaccines. The company also develops seasonal influenza vaccines without preservatives, which completed phase III clinical trials; and human H5N1 influenza vaccine that completed pre-clinical studies. In addition, it exports its products. The company was founded in 2004 and is based in Chengdu, China.
| Last Financial Reports Date | June 30, 2025 |
| Revenue TTM | CN¥1.21 B |
| EBITDA | CN¥324.6 M |
| Gross Profit TTM | CN¥1.12 B |
| Profit Margin | 15.01% |
| Operating Margin | 28.01% |
| Quarterly Revenue Growth | 11.50% |
Chengdu Kanghua Biological Products Co. Ltd has the following listings and related stock indices.
Stock: SZSE: 300841 wb_incandescent